PMV Pharmaceuticals, Inc.

PMVP Nasdaq SEC CIK 1699382
Follow PMV Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$34.4M −63.2% vs same quarter last year
EPS, diluted −$0.52 −30% vs same quarter last year
Operating cash flow −$18.2M +8.3% vs same quarter last year
Operating income −$20.1M +10.9% vs same quarter last year
Net income by quarter
−$23.2M
−$17.4M
−$21.2M
−$21.1M
−$18M
−$18M
−$18.1M
−$34.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
−$80M−$60M−$40M−$20M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$77.7M
FY24−$58.9M
FY23−$69M
FY22−$73.3M
FY21−$57.8M
FY20−$34.4M
FY19−$25.4M
FY18−$17.5M
FY17-
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$73.6M
FY24−$51.9M
FY23−$56.6M
FY22−$71.7M
FY21−$47.9M
FY20−$32.9M
FY19−$22.2M
FY18−$15.6M
FY17-